67 related articles for article (PubMed ID: 1658138)
21. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
22. Effects of WY 47987 (atrial natriuretic factor 102-126) in patients with renal insufficiency: a placebo-controlled, randomised study.
Mann JF; Reisch C; Bergbreiter R; Karcher D; Hackenthal E; Vecsei P; Nussberger J; Ritz E
Nephrol Dial Transplant; 1989; 4(9):776-81. PubMed ID: 2533973
[TBL] [Abstract][Full Text] [Related]
23. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
[TBL] [Abstract][Full Text] [Related]
24. [Hemodynamic and renal effects of synthetic atrial natriuretic factor (alpha-h-ANF) in patients with congestive heart failure].
Fontana F; Guardigli G; Cappelli M; Bernardi P
G Ital Cardiol; 1988 Jul; 18(7):567-77. PubMed ID: 2976692
[TBL] [Abstract][Full Text] [Related]
25. Pressure-dependent distal tubular action of atrial natriuretic peptide in healthy humans.
Eiskjaer H; Nielsen CB; Pedersen EB
J Hypertens; 1996 Jan; 14(1):99-106. PubMed ID: 12013501
[TBL] [Abstract][Full Text] [Related]
26. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Richards AM; Crozier IG; Kosoglou T; Rallings M; Espiner EA; Nicholls MG; Yandle TG; Ikram H; Frampton C
Hypertension; 1993 Jul; 22(1):119-26. PubMed ID: 8391513
[TBL] [Abstract][Full Text] [Related]
27. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure.
Münzel T; Kurz S; Holtz J; Busse R; Steinhauer H; Just H; Drexler H
Circulation; 1992 Oct; 86(4):1089-98. PubMed ID: 1394917
[TBL] [Abstract][Full Text] [Related]
28. Is atrial natriuretic peptide-guanosine 3',5' cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension?
Sagnella GA; Singer DR; Markandu ND; Buckley MG; MacGregor GA
J Hypertens; 1992 Apr; 10(4):349-54. PubMed ID: 1316400
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic, renal, and endocrine actions of ANF in sheep: effect of 24-h, low-dose infusions.
Charles CJ; Espiner EA; Cameron VA; Richards AM
Am J Physiol; 1990 May; 258(5 Pt 2):R1279-85. PubMed ID: 2140028
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
Elsner D; Müntze A; Kromer EP; Riegger GA
Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
[TBL] [Abstract][Full Text] [Related]
31. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
[TBL] [Abstract][Full Text] [Related]
32. Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats.
Scott JM; Barclay PL; Shepperson NB
Eur J Pharmacol; 1993 Sep; 242(1):91-7. PubMed ID: 8223941
[TBL] [Abstract][Full Text] [Related]
33. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake.
Sagnella GA; Markandu ND; Buckley MG; Miller MA; Blackwood A; Singer DR; MacGregor GA
Eur J Clin Invest; 1995 Mar; 25(3):165-70. PubMed ID: 7781662
[TBL] [Abstract][Full Text] [Related]
34. Effects of clonidine and dihydralazine on atrial natriuretic factor and cGMP in humans.
Wehling M; Müller T; Heim JM; Lorenz R; Witzgall H; Weil J; Gerzer R
J Appl Physiol (1985); 1989 Sep; 67(3):938-44. PubMed ID: 2551880
[TBL] [Abstract][Full Text] [Related]
35. Endogenous atrial natriuretic factor after endopeptidase 24.11 inhibition by Thiorphan.
Marleau S; Ong H; Brochu M; Yamaguchi N; de Lean A; du Souich P
Peptides; 1990; 11(2):387-91. PubMed ID: 2141403
[TBL] [Abstract][Full Text] [Related]
36. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension.
Richards AM; Crozier IG; Espiner EA; Yandle TG; Nicholls MG
Hypertension; 1993 Aug; 22(2):231-6. PubMed ID: 8340158
[TBL] [Abstract][Full Text] [Related]
37. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.
Ando S; Rahman MA; Butler GC; Senn BL; Floras JS
Hypertension; 1995 Dec; 26(6 Pt 2):1160-6. PubMed ID: 7498988
[TBL] [Abstract][Full Text] [Related]
38. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition.
Florkowski CM; Richards AM; Espiner EA; Yandle TG; Sybertz E; Frampton CM
Clin Sci (Lond); 1997 Mar; 92(3):255-60. PubMed ID: 9093005
[TBL] [Abstract][Full Text] [Related]
39. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
Westheim AS; Bostrøm P; Christensen CC; Parikka H; Rykke EO; Toivonen L
J Am Coll Cardiol; 1999 Nov; 34(6):1794-801. PubMed ID: 10577572
[TBL] [Abstract][Full Text] [Related]
40. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans.
Barletta G; Lazzeri C; Vecchiarino S; Del Bene R; Messeri G; Dello Sbarba A; Mannelli M; La Villa G
Hypertension; 1998 Mar; 31(3):802-8. PubMed ID: 9495264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
